DUSA Pharmaceuticals, Inc. to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

For release at 8:00 a.m.

Contact:
Shari Lovell, Director, Shareholder Services - 978.657.7500 Ext. 1121
Chad Rubin, Investor Relations Contact, The Trout Group LLC - 646.378.2947

DUSA PHARMACEUTICALS TO PRESENT AT THE
ACUMEN BioFin RODMAN & RENSHAW 9TH ANNUAL HEALTHCARE CONFERENCE

WILMINGTON, MA - October 30, 2007 - DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® photodynamic therapy (PDT) and other products targeting patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Wednesday, November 6, 2007 at 10:55 a.m. ET at The New York Palace Hotel in New York. Interested investors can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website for 14 days following the presentation.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 or Grade 2 actinic keratoses of the face or scalp, and is being studied for the treatment of acne. DUSA's other dermatology products include ClindaReach and Nicomide®. DUSA is also researching additional indications for internal uses of Levulan PDT. DUSA is based in Wilmington, MA. Please visit the company's website at www.dusapharma.com for more information.